Critical Reviews in Immunology最新文献_第9页

Microbiota-Specific Foxp3+ Regulatory T Cells Could Control Pathological T Helper Responses. 微生物特异性Foxp3+调节性T细胞可控制病理性T辅助反应。

IF 1.3 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.2022046412

David Usharauli, Tirumalai Kamala

引用次数: 0

Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management. 继发于免疫检查点抑制剂的皮肤免疫相关不良事件及其处理。

IF 1.3 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.2023046895

J Pach, J S Leventhal

{"title":"Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management.","authors":"J Pach, J S Leventhal","doi":"10.1615/CritRevImmunol.2023046895","DOIUrl":"https://doi.org/10.1615/CritRevImmunol.2023046895","url":null,"abstract":"Immune checkpoint inhibitors (CPIs) are highly effective in the treatment of various cancers. Immunotherapy enhances antitumor activity by relieving inhibition of T cells responsible for immune surveillance. However, overactivation of T cells leads to immune-related adverse events (irAE), of which cutaneous adverse events are the most common. Examples include pruritus and maculopapular eruption most commonly, psoriasis and bullous dermatoses less commonly, and, rarely, severe, life-threatening eruptions such as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. Many of these are autoimmune in nature, and these may present de novo or as recurrence of pre-existing disease. In order to maximize the therapeutic potential of CPIs, it is essential to recognize and effectively manage cutaneous irAE, which can otherwise lead to treatment interruption or discontinuation. This review summarizes the presentation and management of dermatologic adverse events secondary to immune dysregulation as a result of immune checkpoint inhibitor therapy, including the most common (maculopapular eruption, pruritus, lichenoid dermatitis, and vitiligo), less common (psoriasis, bullous pemphigoid, erythema multiforme, eczematous dermatitis, alopecia areata, and granulo-matous and neutrophilic dermatoses), and severe (acute generalized exanthematous pustulosis [AGEP], drug reaction with eosinophilia and systemic symptoms [DRESS], and Stevens-Johnson syndrome or toxic epidermal necrolysis [SJS/TEN]), as well as exacerbation of pre-existing cutaneous autoimmune disease (subacute cutaneous lupus erythematosus, dermatomyositis, eosinophilic fasciitis, leukocytoclastic vasculitis, and scleroderma-like reaction).","PeriodicalId":55205,"journal":{"name":"Critical Reviews in Immunology","volume":"42 4","pages":"1-20"},"PeriodicalIF":1.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9410561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective. 使用自身抗体诊断由免疫检查点抑制剂引发的全身自身免疫疾病:临床观点

IF 1.3 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.2023047272

Alejandra Flores-Chávez, Pilar Brito-Zerón, Soledad Retamozo, Samuel Bitoun, Benjamin A Fisher, David Liew, Karijn Suijkerbuijk, Katerina Chatzidionysiou, María Suárez-Almazor, Olivier Lambotte, Xavier Mariette, Manuel Ramos-Casals

{"title":"Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective.","authors":"Alejandra Flores-Chávez, Pilar Brito-Zerón, Soledad Retamozo, Samuel Bitoun, Benjamin A Fisher, David Liew, Karijn Suijkerbuijk, Katerina Chatzidionysiou, María Suárez-Almazor, Olivier Lambotte, Xavier Mariette, Manuel Ramos-Casals","doi":"10.1615/CritRevImmunol.2023047272","DOIUrl":"https://doi.org/10.1615/CritRevImmunol.2023047272","url":null,"abstract":"Immunotherapies, such as immune checkpoint inhibitors (ICIs), have significantly advanced the treatment of cancer and other conditions. However, these therapies can also cause immune-related adverse events (irAEs), which are unintended side effects due to their effects on the immune system of the treated patient. These effects can be classified as organ-specific or systemic, with the latter being of particular interest due to their potential overlap with systemic autoimmune diseases (SADs). Autoantibodies, which are proteins produced by the immune system that react with self components, are often used to diagnose and classify SAD. However, the diagnostic value of autoantibodies in the context of systemic irAEs (sirAEs) triggered by ICIs is not well understood. This review aims to evaluate the diagnostic value of conventional autoantibodies in the identification and classification of sirAEs. A comprehensive search of the literature was conducted using the PubMed database, with a focus on articles published in the past 10 years. The results of the review suggest that, although autoantibodies can be useful in the diagnosis and classification of some SAD triggered by ICIs, there is a clear predominance of seronegative irAEs. The lack of traditional autoantibodies may suggest a unique mechanism for sirAEs and increases the already complex diagnostic approach of these manifestations, requiring evaluation by multidisciplinary teams with extensive experience in immunomediated diseases. Further research is needed to fully understand the diagnostic value of autoantibodies in this context and to determine the optimal approach for their detection and interpretation.","PeriodicalId":55205,"journal":{"name":"Critical Reviews in Immunology","volume":"42 4","pages":"21-36"},"PeriodicalIF":1.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9410564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IL-18 Gene Promoter Polymorphisms are Involved in Periodontal Disease: A Meta-Analysis. IL-18基因启动子多态性与牙周病有关:一项荟萃分析

IF 1.3 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.2022047290

Preeti Shit, Nisha Sahu, Mohan Krishna Ghanta, Varsha Ahire, Ravindra Jagannath Jadhav, Neha Merchant, L V K S Bhaskar

{"title":"IL-18 Gene Promoter Polymorphisms are Involved in Periodontal Disease: A Meta-Analysis.","authors":"Preeti Shit, Nisha Sahu, Mohan Krishna Ghanta, Varsha Ahire, Ravindra Jagannath Jadhav, Neha Merchant, L V K S Bhaskar","doi":"10.1615/CritRevImmunol.2022047290","DOIUrl":"https://doi.org/10.1615/CritRevImmunol.2022047290","url":null,"abstract":"Microbial plaque that builds up in the gingival crevice area causes inflammation and leads to periodontal disease. Previous research has shown an association between interleukins with periodontitis. The association between interleukin-18 (IL-18) gene polymorphism and periodontitis risk was studied extensively, but the results are contradictory. The aim of this study is to find the association of two IL-18 promoter variants namely -607 C > A (rs1946518) and -137 G > C (rs187238), and the risk of chronic and aggressive periodontal disease by meta-analysis. The databases of PubMed, Medline, Web of Science, and Google Scholar were all explored to find the appropriate studies. The MetaGenyo software was used to calculate each analysis. Outcomes of the pooled analyses revealed significantly elevated risk for periodontitis for both polymorphisms. There is no significant heterogeneity between studies. No significant publication bias was observed. This meta-analysis provided the evidence of a link between IL-18 gene polymorphism in periodontitis.","PeriodicalId":55205,"journal":{"name":"Critical Reviews in Immunology","volume":"42 5","pages":"1-8"},"PeriodicalIF":1.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9419966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Artificial Intelligence and Precision Medicine: Outcome of Immunotherapy in Hepatocellular Carcinoma. 人工智能和精准医学:肝细胞癌免疫治疗的结果。

IF 1.3 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.2022047261

Esube Theodros, Ganji Purnachndra Nagaraju

引用次数: 0

Preface. 序言

IF 0.8 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.v42.i6.10

Benjamin Bonavida, Vipin Kumar

引用次数: 0

The Novel Diagnostic Index Based on HLA-DRB1 Genotype and PD-L1 Expression can Predict Severe irAEs in Patients with Metastatic Melanoma Taking Immune Checkpoint Inhibitors. The Results of the Pilot Study. 基于HLA-DRB1基因型和PD-L1表达的新诊断指标可以预测使用免疫检查点抑制剂的转移性黑色素瘤患者的严重irae。试点研究的结果。

IF 1.3 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.2022045956

N Zhukova, R Orlova, Anna Malkova, E Kaledina, A Demchenkova, P Naimushina, V Nazarov, A Mazing, S Lapin, N Belyak, Y Shoenfeld

{"title":"The Novel Diagnostic Index Based on HLA-DRB1 Genotype and PD-L1 Expression can Predict Severe irAEs in Patients with Metastatic Melanoma Taking Immune Checkpoint Inhibitors. The Results of the Pilot Study.","authors":"N Zhukova, R Orlova, Anna Malkova, E Kaledina, A Demchenkova, P Naimushina, V Nazarov, A Mazing, S Lapin, N Belyak, Y Shoenfeld","doi":"10.1615/CritRevImmunol.2022045956","DOIUrl":"https://doi.org/10.1615/CritRevImmunol.2022045956","url":null,"abstract":"Immune-related adverse events (irAEs) occur in up to 50% of patients treated with an anti-CTLA-4 antibody and 30% of patients treated with PD-1/PD-L1 antibodies. Severe forms of toxicity are observed in 3% of patients and require systemic steroid therapy and constant monitoring. One of the considered predictor biomarkers of irAEs development is HLA-genotypes. This research aims to evaluate the diagnostic significance of HLA-DRB1 genotypes and other clinical and laboratory parameters to predict the development of irAEs. The study involved 28 patients with metastatic melanoma taking checkpoint inhibitors therapy [nivo 53.6%, Ipi+nivo 32.1%, other (pembro, prolgo) 14.3%]. The PD-L1 expression and HLA-DRB1 genotype were evaluated. After 2-3 months the development of irAES was assessed. The complications of 3-4 grade or multi-organ damage were termed as severe irAEs. Various IrAEs developed in 57.1% (16/28) of patients, while severe irAEs occurred in 35.7% (10/28). Among all patients, HLA-DRB1 genotypes associated with the risk of autoimmune diseases were found in 78.5% (22/28). The PD-L1 expression was detected in 60.7% (17/28) of individuals. Combination treatment increases the risk of toxicity, p = 0.0028, with a diagnostic sensitivity of 56% and a diagnostic specificity of 100% (RR = 2.71, OR = 31.67). An index based on the parameters studied (HLA-DRB1, absence of PD-L1 expression, and type of treatment) was created. It allows assuming the risk of developing severe irAES (p = 0.0126). When comparing this indicator between irAEs 1-2 and irAEs 3-4, the presence of an index value of more than 2 gives a sensitivity for predicting severe toxicity of 40.00% and a specificity of 83.33%.","PeriodicalId":55205,"journal":{"name":"Critical Reviews in Immunology","volume":"42 3","pages":"1-9"},"PeriodicalIF":1.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9282957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

NKG2D Ligands in Liquid Biopsy: The Importance of Soluble and Vesicle-Bound Proteins for Immune Modulation. 液体活检中的NKG2D配体:可溶性和囊泡结合蛋白对免疫调节的重要性。

IF 1.3 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.2022045263

Carmen Campos-Silva, Silvia López-Borrego, María José Felgueres, Gloria Esteso, Mar Vales-Gomez

{"title":"NKG2D Ligands in Liquid Biopsy: The Importance of Soluble and Vesicle-Bound Proteins for Immune Modulation.","authors":"Carmen Campos-Silva, Silvia López-Borrego, María José Felgueres, Gloria Esteso, Mar Vales-Gomez","doi":"10.1615/CritRevImmunol.2022045263","DOIUrl":"https://doi.org/10.1615/CritRevImmunol.2022045263","url":null,"abstract":"The identification of biomarkers allowing diagnostics, prognostics and patient classification is still a challenge in oncological research for patient management. Improvements in patient survival achieved with immunotherapies substantiate that biomarker studies rely not only on cellular pathways contributing to the pathology, but also on the immune competence of the patient. If these immune molecules can be studied in a non-invasive manner, the benefit for patients and clinicians is obvious. The immune receptor Natural Killer Group 2 Member D (NKG2D) represents one of the main systems involved in direct recognition of tumor cells by effector lymphocytes (T and Natural Killer cells), and in immune evasion. The biology of NKG2D and its ligands comprises a complex network of cellular pathways leading to the expression of these tumor-associated ligands on the cell surface or to their release either as soluble proteins, or in extracellular vesicles that potently inhibit NKG2D-mediated responses. Increased levels of NKG2D-ligands in patient serum correlate with tumor progression and poor prognosis; however, most studies did not test the biochemical form of these molecules. Here we review the biology of the NKG2D receptor and ligands, their role in cancer and in patient response to immunotherapies, as well as the changes provoked in this system by non-immune cancer therapies. Further, we discuss the use of NKG2D-L in liquid biopsy, including methods to analyse vesicle-associated proteins. We propose that the evaluation in cancer patients of the whole NKG2D system can provide crucial information about patient immune competence and risk of tumor progression.","PeriodicalId":55205,"journal":{"name":"Critical Reviews in Immunology","volume":"42 1","pages":"21-40"},"PeriodicalIF":1.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10670231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Regulatory T Cell Therapeutics for Neuroinflammatory Disorders. 神经炎性疾病的调节性 T 细胞疗法。

IF 0.8 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/CritRevImmunol.2022045080

Ashley L Harkins, Acadia L Kopec, Allison M Keeler

{"title":"Regulatory T Cell Therapeutics for Neuroinflammatory Disorders.","authors":"Ashley L Harkins, Acadia L Kopec, Allison M Keeler","doi":"10.1615/CritRevImmunol.2022045080","DOIUrl":"10.1615/CritRevImmunol.2022045080","url":null,"abstract":"A delicate balance of immune regulation exists in the central nervous system (CNS) that is often dysreg-ulated in neurological diseases, making them complicated to treat. With altered immune surveillance in the diseased or injured CNS, signals that are beneficial in the homeostatic CNS can be disrupted and lead to neuroinflammation. Recent advances in niche immune cell subsets have provided insight into the complicated cross-talk between the nervous system and the immune system. Regulatory T cells (Tregs) are a subset of T cells that are capable of suppressing effector T-cell activation and regulating immune tolerance, and play an important role in neuroprotection. Tregs have been shown to be effective therapies in a variety of immune-related disorders including, graft-versus-host disease (GVHD), type 1 diabetes (T1D), and inflammatory bowel disease (IBD), as well as within the CNS. Recently, significant advancements in engineering T cells, such as chimeric antigen receptor (CAR) T cells, have led to several approved therapies suggesting the safety and efficacy for similar engineered Treg therapies. Further, as understanding of the immune system's role in neuroinflammation has progressed, Tregs have recently become a potential therapeutic in the neurology space. In this review, we discuss Tregs and their evolving role as therapies for neuroinflammatory related disorders.","PeriodicalId":55205,"journal":{"name":"Critical Reviews in Immunology","volume":"42 2","pages":"1-27"},"PeriodicalIF":0.8,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9288055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preface: Immune Response to Viral infections 前言:对病毒感染的免疫反应

IF 1.3 4区医学

Critical Reviews in Immunology Pub Date : 2022-01-01 DOI: 10.1615/critrevimmunol.2022042837

Shashank Tripathi

引用次数: 0